Technical Analysis for NGM - NGM Biopharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade D 18.39 1.77% 0.32
NGM closed up 1.77 percent on Tuesday, July 14, 2020, on 81 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down
Historical NGM trend table...

Date Alert Name Type % Chg
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Stochastic Reached Oversold Weakness 1.77%
Outside Day Range Expansion 1.77%
Wide Bands Range Expansion 1.77%
Down 3 Days in a Row Weakness 1.77%
Down 4 Days in a Row Weakness 1.77%
Oversold Stochastic Weakness 1.77%
Narrow Range Bar Range Contraction -3.87%
Down 3 Days in a Row Weakness -3.87%

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


NGM Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of novel therapeutics for the treatment of cardio-metabolic, liver, oncologic, and ophthalmic diseases. The company's product candidates include NGM282, an engineered variant of the FGF19 human hormone in Phase 2 clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); NGM313, an agonistic antibody that selectively activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase 1b early proof-of-concept clinical trials for use in the treatment of type 2 diabetes and NASH; and NGM386 and NGM395, which are engineered variants of the GDF15 human hormone for use in the treatment of obesity. Its products under development also comprise NGM120, an antagonistic antibody binding glial cell-derived neurotrophic factor receptor alpha-like that is in Phase 1 clinical trials to inhibit the effects of elevated GDF15 levels on cancer anorexia/cachexia syndrome; NGM217, an antibody in Phase 1 clinical trials to restore pancreatic islet function and increase insulin production in patients with diabetes; and NGM621, an antibody in preclinical studies to decrease levels of a protein implicated in the dry form of age-related macular degeneration. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp., MedImmune Limited, and JDRF International. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.
Biotechnology Biopharmaceutical Life Sciences Pharmaceutical Industry Pharmacy Diabetes Monoclonal Antibodies Obesity Age Related Macular Degeneration Treatment Of Obesity

Is NGM a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 23.95
52 Week Low 8.81
Average Volume 312,195
200-Day Moving Average 16.76
50-Day Moving Average 20.66
20-Day Moving Average 20.69
10-Day Moving Average 19.20
Average True Range 1.31
ADX 18.22
+DI 16.38
-DI 25.10
Chandelier Exit (Long, 3 ATRs ) 20.01
Chandelier Exit (Short, 3 ATRs ) 21.94
Upper Bollinger Band 24.09
Lower Bollinger Band 17.30
Percent B (%b) 0.16
BandWidth 32.85
MACD Line -0.59
MACD Signal Line -0.25
MACD Histogram -0.3385
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 19.49
Resistance 3 (R3) 19.48 19.10 19.30
Resistance 2 (R2) 19.10 18.82 19.11 19.24
Resistance 1 (R1) 18.75 18.65 18.93 18.76 19.18
Pivot Point 18.37 18.37 18.46 18.38 18.37
Support 1 (S1) 18.02 18.09 18.20 18.03 17.60
Support 2 (S2) 17.64 17.92 17.65 17.54
Support 3 (S3) 17.29 17.64 17.48
Support 4 (S4) 17.30